Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medicare Reimbursement Policy

Medicare Coverage Policy Change Opens Up Commercial Market Pathway – If Biden Likes It

  • Analysis

Executive Summary

Modification to ‘reasonable and necessary’ definition in MCIT final rule offers new avenue for drug manufacturers to get products covered in Part B. The Biden Administration will have to decide whether it will keep the Trump regulation unchanged.

You may also be interested in...



340B Dispute Resolution Process On Ice As Feuds Between Pharma, Providers, HHS Heat Up

Biden Administration’s regulatory freeze suspends HHS action to appoint an administrative dispute resolution board for the 340B program. Good news for manufacturers?

CMS Drug Coverage Could Be Driven By Commercial Plan Decisions Under Proposal

Proposed rule would also clarify standard for determining whether coverage of a drug, device, or biologic is ‘reasonable and necessary.’

Medicare Will Cover Provenge Labeled Uses, CMS Proposes; Off-Label Is Up To Contractors

Agency decides against requiring coverage with evidence development for off-label uses.

Table

View full table

Related Content

Pink Sheet

Topics

Related Companies

Tags:
Medicare Reimbursement Policy
Latest Headlines

Third Time’s A Charm? US FDA Once Again Proposes Mandatory Consumer Rx Info

Survey Or Shakedown? US Medicaid’s Audacious Negotiation Plan

BIO Notebook: GSK’s Walmsley On M&A; Merck On How Falling Valuations Are Affecting Deals

PBM Reform: Vertical Integration, Specialty Drug Tracking Among Differences In House v. Senate Bills

See All
UsernamePublicRestriction

Register

PS143714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By